Neoadjuvant chemotherapy is part of the standard treatment of organ-confined urothelial carcinoma of the urinary bladder. Due to a large number of studies with new treatment options, it is expected to gain in importance in the coming years.

Patients who respond to neoadjuvant chemotherapy have a significantly improved prognosis. In contrast to other tumor entities, there is currently no tumor regression grading that allows prognosis to be estimated in addition to the staging of any residual tumor. As part of the current retrospective study, regression grading is to be developed using neoadjuvant urothelial carcinomas treated at the six university cancer centers.

The main objective is to establish regression grading for neoadjuvant chemotherapy of urothelial carcinoma of the urinary bladder. Cases from the six university cancer centers will be centrally evaluated histopathologically and correlated with the clinical parameters. In parallel, the staging before and after chemotherapy is also evaluated centrally. Since only relatively few of these patients are treated in each center, the collaboration in a multicenter project offers the opportunity to make valid statements. In addition, this project is intended to create the basis for future translational biomarker studies, prospective IITs and industry-sponsored studies.

• Preparation of the study protocol (2 months)
• Obtaining the ethics vote (3 months)
• Setting up the database (4 months)
• Collection of clinical data, central histopathological findings, central RECIST re-evaluation (9 months)
• Statistical analysis and publication of results (6-10 months)